Vol.53 No.S-1 July 2005
Antimicrobial susceptibility and pharmacokinetics of doripenem in the field of obstetrics and gynecology
1)Division of Anaerobe Research, Life Science Research Center, Gifu University, 1-1 Yanagido, Gifu, Japan
2)Department of Obstetrics and Gynecology, Gifu University Hospital
3)Department of Obsterics and Gynecology, Division of Tumor Control, Gifu University Graduate School of Medicine
Abstract
This study investigated antimicrobial susceptibility of doripenem (DRPM) against clinical isolates from obstetric and gynecologic infections, and the pharmacokinetics of DRPM in plasma, genital tissues, and exudate of the retroperitoneal space. We investigated the in vitro antibacterial activities of DRPM against 33 isolates of Streptococcus agalactiae, 31 of Escherichia coli, 21 of Finegoldia magna, 22 of Bacteroides fragilis, 28 of Prevotella bivia, using an agar dilution method. The MIC50 and MIC90 of DRPM for these strains were 0.25 and 1 μg/mL. DRPM inhibited more than 90% of clinical isolates tested at the concentration of 1 μg/mL. Also, 250 milligram of DRPM was administered to 13 patients for exactly 30 minutes using an automatic drip infusion pump. The concentrations of DRPM in plasma, uterine endometrium, uterine myometrium, oviduct, and ovary were 0.11-18.4 μg/mL, below 0.20-2.89, below 0.20-3.58, below 0.20-2.86, and below 0.20-4.52 μg/g, respectively. The concentration in exudates of retroperitoneal space was 21.9 μg/mL at 1 hour after the end of drip infusion. We could detect DRPM at the concentration of 0.69 μg/mL even at 6 hours after drip infusion. DRPM therefore appears to show considerable potential with excellent antimicrobial activities and satisfactory tissue concentrations against the treatment of obstetric and gynecologic infections.
Key word
doripenem, antibacterial activity, gynecology, pharmacokinetics
Received
January 11, 2005
Accepted
February 9, 2005
Jpn. J. Chemother. 53 (S-1): 286-292, 2005
